Eman, I have not by any stretch conceded that Vitaros is a niche drug (as one poster often states) because it addresses a very large unmet need. A niche drug is more often used in context with treating a rare disease.
Paying the bills (and establishing a solid income stream) is a good way of characterizing what we need for the next couple of years. I agree, licensing out RayVa would also be a good way of raising a little cash.
Market Data 
Markets 
AI
